Therapeutic effect of Zhibitai combined with atorvastatin in the treatment of coronary heart disease with hyperlipidemia and its influence on the level of hypersensitive C-reactive protein

医学 阿托伐他汀 高脂血症 内科学 甘油三酯 C反应蛋白 冠心病 胃肠病学 血脂 入射(几何) 不利影响 胆固醇 高密度脂蛋白 冠状动脉疾病 急性冠脉综合征 心脏病学 内分泌学 炎症 心肌梗塞 糖尿病 物理 光学
作者
Tong Lu,Bin Tan,Tingting Deng,Yongping Hua,Gang Xu
出处
期刊:Chinese Journal of Primary Medicine and Pharmacy 卷期号:26 (24): 3022-3025
标识
DOI:10.3760/cma.j.issn.1008-6706.2019.24.020
摘要

Objective To study the effect of atorvastatin combined with Zhibitai in the treatment of coronary heart disease with hyperlipidemia and its influence on the level of high-sensitivity C-reactive protein(hsCRP). Methods A total of 136 patients with coronary heart disease and hyperlipidemia admitted to the Third People's Hospital of Jingdezhen from September 2016 to September 1818 were randomly divided into control group and combination group using stochastic comprehensive balance method, with 68 cases in each group.The control group was treated with atorvastatin and the combination group was treated with lipidine plus atorvastatin. The patient's treatment effect, including the blood lipid compliance rate and the occurrence of adverse reactions during the treatment were observed, as well as the patient's pre-and post-treatment triglyceride(TG), 12h serum total cholesterol(TC), high-density lipoprotein-cholesterol(HDL-C), low density lipoprotein-cholesterol(LDL-C)and high-sensitivity C-reactive protein(hsCRP)and other indicators were measured. Results (1)The blood lipid compliance rate(89.86%) in the combined group was higher than that in the control group(59.70%), the difference was statistically significant(χ2=14.915, P=0.000). (2)The incidence of adverse reactions in the combined group(1.45%) was lower than that in the control group(17.91%), the difference was statistically significant(χ2=8.836, P=0.003). (3)The results showed that the TC, TG, LDL-C, hsCRP and other indicators of the combined group were lower than those of the control group and before treatment, while the HDL-C index of the combined groupwas higher than that of the control group and before treatment, the differences were statistically significant(t=20.800, 4.903, 11.657, 4.346, 6.262, P=0.000, 0.000, 0.000, 0.000, 0.000). Conclusion Zhibitai combined with atorvastatin in the treatment of coronary heart disease patients with hyperlipidemia has remarkable effect.It can accurately control TC, TG, LDL-C, HDL-C and hsCRP, improve blood lipid control rate. Key words: Coronary artery disease; Hyperlipidemias; Lipoproteins, HDL; Cholesterol, LDL; C-Reactive protein; Triglycerides; Adverse reactions; Zhibitai; Atorvastatin

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
11完成签到,获得积分20
刚刚
1秒前
molihuakai应助111采纳,获得10
1秒前
ding应助科研通管家采纳,获得10
1秒前
烟花应助科研通管家采纳,获得10
1秒前
1秒前
1秒前
搜集达人应助科研通管家采纳,获得10
2秒前
2秒前
完美世界应助科研通管家采纳,获得10
2秒前
Copyright应助科研通管家采纳,获得10
2秒前
领导范儿应助科研通管家采纳,获得10
2秒前
乐乐应助科研通管家采纳,获得10
2秒前
科研通AI2S应助科研通管家采纳,获得10
2秒前
2秒前
2秒前
2秒前
传奇3应助科研通管家采纳,获得10
2秒前
天天快乐应助科研通管家采纳,获得10
3秒前
tyx发布了新的文献求助10
3秒前
华仔应助科研通管家采纳,获得10
3秒前
3秒前
3秒前
耸耸完成签到 ,获得积分10
3秒前
黄淮海发布了新的文献求助10
3秒前
充电宝应助文艺代灵采纳,获得10
4秒前
西地兰卡发布了新的文献求助10
4秒前
哎亚亚发布了新的文献求助10
5秒前
conghuiqu完成签到,获得积分10
6秒前
LeezZZZ发布了新的文献求助10
6秒前
6秒前
一路生花发布了新的文献求助10
6秒前
SciGPT应助malenia采纳,获得10
7秒前
7秒前
隐形曼青应助zoey采纳,获得10
7秒前
7秒前
7秒前
狂野世立完成签到,获得积分10
8秒前
9秒前
连仁兄发布了新的文献求助10
9秒前
高分求助中
Cronologia da história de Macau 5000
Merrill's Atlas of Radiographic Positioning and Procedures - 3-Volume Set, 16th Edition 2000
Erwählung und Berufung bei Paulus: Bedeutung, Entwicklung und Funktion einer Vorstellung in ihrem frühjüdischen und griechisch-römischen Kontext 850
Matrix Methods in Data Mining and Pattern Recognition 510
Interactions of Vowel Quality and Prosody in East Slavic 500
Vander's Renal Physiology第10版 500
CLSI M27M44S Performance Standards for Antifungal Susceptibility Testing of Yeasts Fourth Edition 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7118849
求助须知:如何正确求助?哪些是违规求助? 8771344
关于积分的说明 18547847
捐赠科研通 6691711
什么是DOI,文献DOI怎么找? 3147211
关于科研通互助平台的介绍 2265232
邀请新用户注册赠送积分活动 2121757